Suzhou Ribo Life Science, a China-based clinical-stage biotech with a focus on nucleic acid research,raised USD40m in the first tranche of a Series E led by Panlin Capital and Sany Foundation’s Trinity Innovation Fund, with participation from new investors. The startup raised a CNY673m (~USD95m) Series C in 2020 from China state-owned Capital Venture Investment Fund, Legend Capital, CICC Capital, GL Ventures and others. Read more